Enrollment of 700 Patients Completed Ahead of Schedule
Case Study
Jan 30, 2020
Strategic patient recruitment process reduced enrollment timelines for two Phase II psoriasis studies
A leading global pharmaceutical company with a focus on dermatology selected IQVIA Biotech to conduct two large, Phase II psoriasis studies involving a combined 700 patients at 40 sites. IQVIA Biotech was challenged to achieve the sponsor’s goal of randomizing 300 scalp/body psoriasis and 400 body-only psoriasis patients in an 18-week period, from early May through the end of August, a difficult time of year for enrollment of this condition. Our strategic patient recruitment process reduced enrollment timelines, enrolling all patients weeks ahead of schedule.